Initial high expression of IL-10RA is not predictive of clinical outcome for patients treated with chemotherapy. (A) Schematic summary of diagnostic biopsy specimens of ALK⁺ ALCL patient tumors analyzed by immunohistochemistry. Numbers of standard ALCL99 chemotherapy–treated patients who presented with a “relapse” or “no relapse” are indicated below each chart. (B) Percentage of tumor cells expressing IL-10RA in diagnostic biopsy specimens of patients in (A) (n = 98) who were treated with standard ALCL99 chemotherapy. Individual quantifications are plotted, with mean ± standard deviation indicated. (C-D) Pediatric patients (n = 92) treated with standard ALCL99 chemotherapy as part of the NHL-BFM90, NHL-BFM95, and ALCL99 trials were divided into 2 groups (low < 50% and high ≥ 50%), according to the percentage of tumor cells expressing IL-10RA. The difference in median EFS (C) or OS (D) (log-rank test) was analyzed using the Kaplan-Meier estimator. ns, not significant.